IRIS
IACOBELLI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.355
AS - Asia 2.193
EU - Europa 1.363
SA - Sud America 387
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 7
Totale 21.357
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.315
SG - Singapore 1.068
BR - Brasile 322
CN - Cina 304
KR - Corea 280
HK - Hong Kong 266
UA - Ucraina 205
IT - Italia 191
SE - Svezia 180
IE - Irlanda 163
DE - Germania 160
RU - Federazione Russa 147
GB - Regno Unito 112
FI - Finlandia 66
VN - Vietnam 59
ID - Indonesia 45
FR - Francia 32
JP - Giappone 31
IN - India 25
NL - Olanda 24
AR - Argentina 23
AT - Austria 23
CA - Canada 22
CO - Colombia 19
BD - Bangladesh 13
IQ - Iraq 13
GH - Ghana 12
IR - Iran 12
PL - Polonia 12
BE - Belgio 11
CZ - Repubblica Ceca 11
PH - Filippine 11
MX - Messico 10
TR - Turchia 10
CL - Cile 9
PK - Pakistan 9
ES - Italia 8
EU - Europa 8
ZA - Sudafrica 8
AU - Australia 7
JO - Giordania 6
MA - Marocco 6
SA - Arabia Saudita 6
GR - Grecia 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
DZ - Algeria 4
EG - Egitto 4
KE - Kenya 4
NP - Nepal 4
EC - Ecuador 3
IL - Israele 3
KZ - Kazakistan 3
MY - Malesia 3
NO - Norvegia 3
UY - Uruguay 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CR - Costa Rica 2
JM - Giamaica 2
PA - Panama 2
PE - Perù 2
PY - Paraguay 2
RO - Romania 2
RS - Serbia 2
TH - Thailandia 2
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
CH - Svizzera 1
DK - Danimarca 1
GE - Georgia 1
GT - Guatemala 1
IS - Islanda 1
LB - Libano 1
LT - Lituania 1
MD - Moldavia 1
ML - Mali 1
MW - Malawi 1
OM - Oman 1
PS - Palestinian Territory 1
SN - Senegal 1
TG - Togo 1
TJ - Tagikistan 1
TM - Turkmenistan 1
TT - Trinidad e Tobago 1
Totale 21.357
Salva come PNG Salva come JPEG
Città #
Woodbridge 4.667
Wilmington 4.368
Houston 4.069
Fairfield 666
Singapore 479
Ann Arbor 388
Ashburn 368
Seattle 277
Chandler 271
Hong Kong 261
Cambridge 247
Creede 202
Dublin 156
Jacksonville 149
Santa Clara 147
Medford 137
Beijing 103
Rome 76
Lawrence 61
Dearborn 57
Los Angeles 52
New York 51
Buffalo 47
Zhengzhou 42
Moscow 41
Nanjing 38
Jakarta 37
The Dalles 37
San Diego 31
Milan 30
London 29
Redwood City 26
Nuremberg 24
São Paulo 24
Philadelphia 23
Ho Chi Minh City 22
Scottsdale 21
Shanghai 21
Hanoi 18
Petaluma 18
Dallas 15
Redondo Beach 15
Rio de Janeiro 13
Accra 12
Belo Horizonte 12
Chicago 12
Seoul 12
Brussels 11
Mülheim 11
Toronto 11
Bogotá 10
Norwalk 10
Warsaw 10
Council Bluffs 9
Tokyo 9
Turku 9
Brooklyn 8
Manila 8
Stockholm 8
Boardman 7
Brno 7
Helsinki 7
Kilburn 7
Lappeenranta 7
Munich 7
Nanchang 7
Pereira 7
Phoenix 7
Roppongi 7
Vienna 7
Wuhan 7
Amman 6
Baghdad 6
Brasília 6
Chennai 6
Hefei 6
Kunming 6
Las Vegas 6
Center 5
Denver 5
Geumcheon-gu 5
Groningen 5
Guangzhou 5
Haeundae-gu 5
Montreal 5
Naples 5
Richardson 5
Washington 5
Amsterdam 4
Atlanta 4
Baku 4
Boston 4
Campinas 4
Curitiba 4
Engelhard 4
Enterprise 4
Falls Church 4
Guarulhos 4
Hangzhou 4
Hounslow 4
Totale 18.210
Salva come PNG Salva come JPEG
Nome #
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial) 635
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT) 518
Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation 489
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. 447
Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study 445
Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study 445
Salvage use of allogeneic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the EBMT Chronic Malignancies Working Party 439
Multiple time scales in multi-state models 422
Efficacy and outcome of autologous transplantation in rare myelomas 422
Outcome of patients developing GvHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT 418
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. 417
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation 416
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia 414
Assessment of the role of timing of second transplantation in multiple myeloma by multistate modeling 414
Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? 410
Stem cell transplantation for chronic myeloid leukemia in children 408
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia 406
Partially anaortic clampless off-pump coronary artery bypass prevents neurologic injury compared to on-pump coronary surgery: a propensity score-matched study on 286 patients 406
Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research 406
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation 405
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party 402
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia 401
Protective Environment for Hematopoietic Cell Transplant (HSCT) Recipients: The Infectious Diseases Working Party EBMT Analysis of Global Recommendations on Health-Care Facilities 401
Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in myeloma: long-term follow-up 397
Current practices used for the prevention of central venous catheter-associated infection in hematopoietic stem cell transplantation recipients: a survey from the Infectious Diseases Working Party and Nurses' Group of EBMT 395
Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties 392
Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia 383
Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 381
Lymphoproliferative Disorders After Hematopoietic Stem Cell Transplantation in Children and Adults: a Study From the Infectious Diseases Working Group of the European Group for Blood and Marrow Transplantation 378
Autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study 376
Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation 375
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group 372
High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation 369
The Cox shared frailty model with log-skew-normal frailties 367
Length of stay in different drug using states: lifestyles of problem and recreational drug consumers 367
Survival probabilities with time-dependent treatment indicator: quantities and non-parametric estimators 363
Melphalan 140mg/M2 Or 200mg/M2 For Autologous Transplantation In Myeloma: Results From The Collaboration To Collect Autologous Transplant Outcomes In Lymphoma And Myeloma (CALM) Study. A Report By The EBMT Chronic Malignancies Working Party 363
Allogenic hematopoietic stem cell transplantation in patients with polycythemia or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: report from the MPN subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 359
Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation 359
Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents. 355
Primary plasma cell leukemia and autologous stem cell transplantation 351
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT 350
Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia 342
Impact of complete remission before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial 340
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. 325
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion 313
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. 311
Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma 287
Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita 260
Allogeneic transplantation in multiple myeloma - Does it still have a place? 136
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL) 136
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy 99
Pollen variability in Quercus L. species and relative systematic implications 86
Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT) 86
Conditioning-based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991-2012) on behalf of EBMT CMWP 84
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modelling 79
Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT 77
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors 71
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor 69
Analyzing differences between restricted mean survival time curves using pseudo-values 69
Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT 68
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation 65
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT 63
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation 62
Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: a study on behalf of the European blood and marrow transplant severe aplastic anemia working party. 62
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT 62
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia 62
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes 60
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study 60
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT 60
Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation 59
Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 58
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101 55
Intercontinental study on pre-engraftment and post-engraftment Gram-negative rods bacteremia in hematopoietic stem cell transplantation patients: risk factors and association with mortality 52
Impact of donor-derived CD34+infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT 51
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma 50
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study 50
Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP 50
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma 44
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications 44
Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation 44
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia 44
Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation 43
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison 41
The effect of prior exposure to imatinib on transplant-related mortality 40
Outcomes and toxicity of allogeneic HCT in CML patients previously treated with second generation TKIs: a prospective non-interventional study from the Chronic Malignancy Working Party of EBMT 40
Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study 40
Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning 34
Role of stem cell transplantation in myeloma 33
Statistical methods in HSCT and cellular therapies 33
Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia 32
Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors 29
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants 27
Totale 21.825
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.413
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.413
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.565 0 0 0 0 0 505 512 213 86 96 124 29
2021/2022778 41 87 85 53 21 51 43 27 35 56 58 221
2022/20231.382 89 77 40 77 76 206 412 229 78 18 44 36
2023/2024387 34 18 29 28 45 54 34 22 32 28 8 55
2024/20251.795 51 408 190 111 15 172 118 68 192 175 130 165
2025/20261.189 199 211 366 156 176 81 0 0 0 0 0 0
Totale 21.825